ENDEAVOR Sample Clauses

ENDEAVOR. By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- PB CAPITAL CORPORATION, as a Lender By: /s/ Jeffrey Frost ------------------------------------------- Name: Jeffrey Frost ----------------------------------------- Title: Managing Director/Portfolio Management ---------------------------------------- By: /s/ Andrew Shipman ------------------------------------------- Name: Andrew Shipman ----------------------------------------- Title: Assistant Vice President/ ---------------------------------------- Portfolio Management ---------------------------------------- APEX (IDM) CDO I By: /s/ Glenn Duffy ------------------------------------------- Name: Glenn Duffy ----------------------------------------- Title: Director ---------------------------------------- CYPRESSTREE INVESTMENT PARTNERS II, LTD. By: Cypress Tree Investment Management Company, Inc. as Portfolio Manager By: /s/ Jeffrey Megar ------------------------------------------- Name: Jeffrey Megar ----------------------------------------- Title: Principal ---------------------------------------- ELC CAYMAN CDO SERIES 1999-1 By: /s/ Glenn Duffy ------------------------------------------- Name: Glenn Duffy ----------------------------------------- Title: Director ---------------------------------------- ELC CAYMAN LTD. 2000-1 By: /s/ Glenn Duffy ------------------------------------------- Name: Glenn Duffy ----------------------------------------- Title: Director ---------------------------------------- GRAYSON & CO By: /s/ Barbara Campbell ------------------------------------------- Name: Barbara Campbell ----------------------------------------- Title: Vice President ---------------------------------------- GRAYSON CLO 2001-01 LTD. By: Bear Stearns Asset Management Inc. as its Collateral Manager By: /s/ Niall D. Rosenzweig ------------------------------------------- Name: Niall D. Rosenzweig ----------------------------------------- Title: Associate Director ---------------------------------------- JH WHITNEY MARKET VALUE FUND By: /s/ Marc S. Diagonale ------------------------------------------- Name: Marc S. Diagonale ----------------------------------------- Title: Authorized Signatory ---------------------------------------- KATONAH I, LTD. By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- KATONAH II, LTD. By: ----...
ENDEAVOR. By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- PB CAPITAL CORP. NY By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- APEX (IDM) CDO I By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- CYPRESSTREE INVESTMENT PARTNERS II By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- ELC CAYMAN CDO SERIES 1999-1 By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- ELC CAYMAN LTD. 2000-1 By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- GRAYSON & CO By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- GRAYSON CLO 2001-01 LTD. By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- JH WHITNEY MARKET VALUE FUND By: /s/ ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- KATONAH I, LTD. By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- KATONAH II, LTD. By: ------------------------------------------- Name: ----------------------------------------- Title: ---------------------------------------- KZH PAMCO By: ------------------------------------------- Name: ----------------------------------------- Title: ----------------------------------------
ENDEAVOR expressly agrees that all data, information and knowledge received by ENDEAVOR from ORGANICS relative to the business, operations, customers, sales, distribution, or suppliers, and/or to the manufacture, formulation or production of Conjugated Estrogens and/or other Estrogen Sulfates, whether Substance or other APIs, shall be deemed the Confidential Information of ORGANICS. Such Confidential Information of ORGANICS shall include that specifically revealed to ENDEAVOR by ORGANICS, as well as that acquired by ENDEAVOR through its observations, investigations and activities within the facilities of ORGANICS and also that acquired by ENDEAVOR from its patent counsel regarding ORGANICS' process for the synthesis of Substance. ENDEAVOR shall not disclose any Confidential Information of ORGANICS to any third party, nor shall ENDEAVOR use the Confidential Information of ORGANICS except for purposes provided for in this Agreement, or necessary to carry out the provisions of this Agreement. Specifically, all intellectual property, whether patented or not, trade secrets and know-how on the structure and formulation of Substance and/or any other Estrogen Sulfate API, all items which contribute to the formulation of the key intermediates which are used to manufacture Substance, the stability thereof, techniques, evaluations, the formulations and related methods, know-how, data, design, formulas, compositions, specifications, compounds, materials, processes, discoveries, equipment, machines, inventions, trade secrets, methods, steps, procedures and/or computer programs related to the technology or methodology involved in the development, manufacture or production of Substance or other Estrogen Sulfate APIs, disclosed to ENDEAVOR by ORGANICS are and shall remain the property of ORGANICS and shall be deemed Confidential Information of ORGANICS as herein defined.
ENDEAVOR shall not, and shall take commercially reasonable steps to ensure that the Hospitals do not, make any representations with respect to the content and/or ownership of the NCI Software, the SDKs or the Betas.
ENDEAVOR expressly agrees that ENDEAVOR and/or any other parties involved in the formulation, manufacturing and distribution of Product are solely responsible for Product stability and that ORGANICS' warranty obligations with respect to stability extend solely to Substance. In no event does ORGANICS warrant that Substance will meet Specifications after its labeled re-evaluation date has passed and, under such circumstances, ORGANICS will neither replace Substance nor refund the amount paid by ENDEAVOR. Except where the provisions of Section 4.7 apply, in the event that ENDEAVOR and ORGANICS disagree with respect to the current potency of Substance under this warranty, then ORGANICS' analysis of ORGANICS' retained stability sample of the specific Batch of Substance in question shall be the sole determination of the potency of Substance. Analytical data generated by ORGANICS in connection with a claim under this warranty shall be supplied to ENDEAVOR upon request. Notwithstanding the above, ORGANICS will not and does not warrant that Substance will meet Specifications if ENDEAVOR or its agents and/or its Contract Manufacturer has not stored and/or handled such Substance according to labeling, and in compliance with relevant GMPs. These limited warranties are extended to ENDEAVOR and shall not be assignable, transferable, or extended to any other party except under the provisions of Section 10.3 herein. IN NO EVENT SHALL ANY ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY ORGANICS, ITS EMPLOYEES, DISTRIBUTORS, DEALERS OR AGENTS INCREASE THE SCOPE OF THE WARRANTIES IN THIS AGREEMENT OR CREATE ANY NEW WARRANTIES HEREUNDER. THESE LIMITED WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE HEREBY EXPRESSLY EXCLUDED.
ENDEAVOR expressly agrees that the manufacturing and control procedures and technology used by ORGANICS to manufacture Substance are, and shall remain, the property of ORGANICS, and are part of one or more ORGANICS' DMFs which are, and shall remain, the property of ORGANICS. ORGANICS agrees that so long as ENDEAVOR remains in compliance with the terms of this Agreement and so long as this Agreement remains in full force and effect, it will allow ENDEAVOR to reference the above mentioned DMFs for incorporation by reference of such parts thereof as may be required into ENDEAVOR'S NDA(s) for all Product derived from Substance under this Agreement. If this Agreement terminates in accordance with Article 8 hereof, ENDEAVOR may refer to such DMFs for a reasonable time, which shall not be less than the time required to sell sufficient Product to use inventory of Substance, provided it gives ORGANICS notice thereof.
ENDEAVOR shall not, and shall ensure that the Hospitals do not, use the NCI Logo or any NCI trademarks or any other 8 mark likely to cause confusion with the NCI trademarks as any portion of ENDEAVOR's 9 tradename, trademark for the NCI Software, or trademark for any other products of ENDEAVOR. All such usage shall inure to NCI's benefit. ENDEAVOR shall not, and shall ensure that the Hospitals do not, register any NCI Logos without NCI's express prior written consent. ENDEAVOR shall not, and shall ensure that the Hospitals do not, contest NCI's ownership of, or rights in, the NCI Logos. From time to time, at NCI's request, ENDEAVOR shall, and shall require the Hospitals to, supply a reasonable number of samples of the NCI Software, Software Documentation, and all other materials bearing any of the NCI Logo so that NCI may conduct quality control reviews to ensure that usage of the NCI Logo complies with the terms of this section including, without limitation, NCI's trademark policies, branding requirements and other NCI standards for such usage. In the event that NCI notifies ENDEAVOR that ENDEAVOR or a Hospital(s) has failed to comply as set forth herein, ENDEAVOR shall, and/or shall ensure that the Hospital, suspend distribution and use of the NCI Software until ENDEAVOR has satisfied NCI that the foregoing requirements have been met. ENDEAVOR agrees with respect to each registered trademark of NCI, to include, and shall require the Hospitals to include, in each advertisement, brochure, or other such use of the trademark, the trademark symbol "circle R" and the following statement: ______is a registered trademark of Network Computer, Inc., Redwood Shores, California Unless otherwise notified in writing by NCI, ENDEAVOR agrees with respect to the NCI Logo trademark of NCI and to every other trademark of NCI, to include, and shall require the Hospitals to include, in each advertisement, brochure, or other such use of the trademark, the symbol "TM" and the following statement: __(NCI Logo/trademark)__ is a trademark of Network Computer, Inc., Redwood Shores, California ENDEAVOR shall not, and shall ensure that the Hospitals do not, market the NCI Software in any way which implies that the NCI Software is the proprietary product of ENDEAVOR or of any party other than NCI. NCI shall not have any liability to ENDEAVOR or the Hospitals for any claims made by third parties relating to ENDEAVOR's or the Hospitals use of NCI's trademarks.
ENDEAVOR shall cease using and destroy all copies of any Betas provided hereunder upon the earlier of (a) NCI's delivery of the production version of such software; (b) NCI's written notice to ENDEAVOR; and (c) termination of this Agreement.
ENDEAVOR. West 2809 Longfellow Spokane, WA 99205 ECC --- 521-3 Avenue SW Calgary, Alberta, Canada T2P 3T3